- Correction
- Open access
- Published:
Correction: Comprehensive review of CRISPR‑based gene editing: mechanisms, challenges, and applications in cancer therapy
Molecular Cancer volume 23, Article number: 43 (2024)
The Original Article was published on 09 January 2024
Correction: Mol Cancer 23, 9 (2024)
https://doi.org/10.1186/s12943-023-01925-5
Following publication of the original article [1], it has come to the author's attention that this article cites their work in an incorrect fashion and at least the related part of the paper raises some concern about the integrity of the reported information.
In Table 3 on clinical trials of CRISPR-based therapy of the manuscript, the authors cite our study (Ref 202 in the article, https://doi.org/10.1016/j.omtm.2022.03.018) and claim they demonstrated HPRT1-KO in cancer cells as a treatment strategy. Unfortunately, this statement does not reflect our study. They demonstrated for the first time that non-viral knock-in of CD19-specific CAR into primary human T cells is possible and effective with non-viral dsDNA templates (e.g. related to Fig. 11 of the Molecular Cancer article). This study was completely pre-clinical and had no relation to HPRT1.
After this perplexing finding, the corresponding author took some time to check other references of Table 3 and discovered that other references (such as References 201, 198, 197 that he checked) were also wrong. Glancing at other references in Table 3, it seems the authors cited predominantly review articles instead of original articles and at least some of the content was completely misaligned to the topic (e.g. Ref 198 cites a review on transplantation and GvhD; no relation to cancer therapy). Some of the related content is also non-sensical, suggesting either inexperience by the person preparing the table or potentially the use of a flawed AI tool. The correct Table 3 is given below.
References
Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, et al. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer. 2024;23:9. https://doi.org/10.1186/s12943-023-01925-5.
Liu Q. World-first phase I clinical trial for CRISPR-Cas9 PD-1-edited T-cells in advanced nonsmall cell lung cancer. Glob Med Genet. 2020;7:073–4.
Zhen S, Li X. Oncogenic human papillomavirus: application of CRISPR/Cas9 therapeutic strategies for cervical cancer. Cell Physiol Biochem. 2018:2455–66.
Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med. 2020;26:732–40.
Ottaviano G, Georgiadis C, Gkazi SA, Syed F, Zhan H, Etuk A, et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci Transl Med. 2022;14.
Khan A, Sarkar E. CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer. Cancer Treat Res Commun. 2022.
Crispo F, Pietrafesa M, Condelli V, Maddalena F, Bruno G, Piscazzi A, et al. IDH1 Targeting as a new potential option for intrahepatic cholangiocarcinoma treatment—current state and future perspectives. Molecules. 2020.
Mirgayazova R, Khadiullina R, Chasov V, Mingaleeva R, Miftakhova R, Rizvanov A, et al. Therapeutic editing of the TP53 gene: Is crispr/CAS9 an option? Genes (Basel). 2020:1–17.
Chamberlain CA, Bennett EP, Kverneland AH, Svane IM, Donia M, Met Ö. Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy. Mol Ther - Oncolytics. 2022;24:417–28.
Bamdad CC, Yuan Y, Specht JM, Stewart AK, Smagghe BJ, Lin SC-M, et al. Phase I/II first-in-human CAR T–targeting MUC1 transmembrane cleavage product (MUC1*) in patients with metastatic breast cancer. J Clin Oncol. 2022;40:TPS-1130.
Alishah K, Birtel M, Masoumi E, Jafarzadeh L, Mirzaee HR, Hadjati J, et al. CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro. J Transl Med. 2021;19.
Hedrich V, Breitenecker K, Ortmayr G, Pupp F, Huber H, Chen D, et al. PRAME is a novel target of tumor-intrinsic Gas6/Axl activation and promotes cancer cell invasion in hepatocellular carcinoma. Cancers (Basel). 2023;15.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Chehelgerdi, M., Chehelgerdi, M., Khorramian‑Ghahfarokhi, M. et al. Correction: Comprehensive review of CRISPR‑based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer 23, 43 (2024). https://doi.org/10.1186/s12943-024-01961-9
Published:
DOI: https://doi.org/10.1186/s12943-024-01961-9